Jonathan Rubin - 25 Sep 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Chief Medical Officer
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
25 Sep 2025
Net transactions value
-$38,816
Form type
4
Filing time
26 Sep 2025, 16:17:29 UTC
Previous filing
12 Sep 2025
Next filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rubin Jonathan SVP, Chief Medical Officer C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 26 Sep 2025 0001836067

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +1,875 +19% $0.000000 11,855 25 Sep 2025 Direct F1
transaction SUPN Common Stock Tax liability $38,816 -840 -7.1% $46.21 11,015 25 Sep 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Unit Options Exercise $0 -1,875 -100% $0.000000 0 25 Sep 2025 Common Stock 1,875 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024.
F2 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3 On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.